FY2027 Earnings Forecast for Vaxart Issued By B. Riley

Vaxart, Inc. (NASDAQ:VXRT) – Equities researchers at B. Riley issued their FY2027 EPS estimates for Vaxart in a note issued to investors on Monday, November 18th. B. Riley analyst M. Mamtani forecasts that the biotechnology company will post earnings per share of $0.09 for the year. The consensus estimate for Vaxart’s current full-year earnings is ($0.43) per share. B. Riley also issued estimates for Vaxart’s FY2028 earnings at $0.13 EPS.

Separately, Oppenheimer assumed coverage on shares of Vaxart in a research report on Thursday, August 15th. They set an “outperform” rating and a $4.00 target price on the stock.

Vaxart Stock Down 1.4 %

NASDAQ:VXRT opened at $0.60 on Wednesday. Vaxart has a 12 month low of $0.52 and a 12 month high of $1.54. The firm has a market cap of $106.33 million, a price-to-earnings ratio of -1.46 and a beta of 0.70. The company’s 50 day moving average is $0.78 and its 200-day moving average is $0.77.

Institutional Investors Weigh In On Vaxart

Institutional investors have recently bought and sold shares of the business. Mesirow Financial Investment Management Inc. boosted its stake in shares of Vaxart by 100.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 20,000 shares in the last quarter. Tidal Investments LLC acquired a new stake in shares of Vaxart in the 1st quarter valued at $56,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Vaxart in the 2nd quarter valued at $65,000. XTX Topco Ltd boosted its stake in shares of Vaxart by 869.3% in the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 122,387 shares in the last quarter. Finally, Monaco Asset Management SAM acquired a new stake in shares of Vaxart in the 2nd quarter valued at $402,000. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.